Experimental combo aims to boost immune attack on tough lung cancers

NCT ID NCT05879978

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when combined with ezabenlimab. Up to 45 participants will receive treatment for up to 3 years, with regular monitoring for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Obrixtamig (BI 764532) and ezabenlimab
What this could lead to: If this combination is safe and shows signs of shrinking tumors, it could point toward a new treatment option for people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 45 participants, so the main goal is safety and dosing, not proof of effectiveness. The drugs may cause side effects, and there is no guarantee they will work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm pulmonary large cell neuroendocrine carcinoma small cell carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASMS SMALL CELL LUNG CARCINOMA (SCLC)

Contacts and locations

Locations

CTR François Baclesse

Caen, 14000, France
Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Hôpital Louis Pradel

Bron, 69677, France
INS Claudius Regaud IUCT-Oncopole

Toulouse, 31059, France
National Cancer Center Hospital

Tokyo, Chuo-ku, 104-0045, Japan
Technische Universität Dresden

Dresden, 01307, Germany
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
Universitätsklinikum Frankfurt

Frankfurt, 60590, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.